Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells

Antioxidants and Redox Signaling

Volumn 23, Issue 1, 2015, Pages 66-84

  Chueh, Anderly C ^a   Tse, Janson W T ^a   Tögel, Lars ^a   Mariadason, John M ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; PROTEIN P53; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CHROMATIN; CLINICAL TRIAL (TOPIC); CUTANEOUS T CELL LYMPHOMA; GENE; GENE EXPRESSION; GROWTH INHIBITION; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TRANSFORMED CELL; ANIMAL; CELL DIFFERENTIATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

ACETYLATION; ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS;

EID: 84934937334     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5863     Document Type: Review

References (190)

1. Agricola E, Randall RA, Gaarenstroom T, Dupont S, and Hill CS. Recruitment of TIF1gamma to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 43: 85-96, 2011.
2. Allfrey VG. Post-synthetic modifications of histone structure: a mechanism for the control of chromosome structure by the modulation of histone-DNA interactions. In: Chromatin and Chromosome Structure, edited by Li HJ and Eckhardt RE. New York: Academic, 1977, pp. 167-191.
3. Allfrey VG, Faulkner R, and Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci U S A 51: 786-794, 1964.
4. Amin MR, Dudeja PK, Ramaswamy K, and Malakooti J. Involvement of Sp1 and Sp3 in differential regulation of human NHE3 promoter activity by sodium butyrate and IFN-gamma/TNF-alpha. Am J Physiol Gastrointest Liver Physiol 293: G374-G382, 2007.
5. Ammanamanchi S, Freeman JW, and Brattain MG. Acetylated sp3 is a transcriptional activator. J Biol Chem 278: 35775-35780, 2003.
6. Ansari SA and Morse RH. Mechanisms of mediator complex action in transcriptional activation. Cell Mol Life Sci 70: 2743-2756, 2013.
7. Archer SY, Meng S, Shei A, and Hodin R. p21WAF1 is required for butyrate-mediated growth inhibition of colon cancer cells. Proc Natl Acad Sci U S A 95: 6791-6796, 1998.
8. Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, and Remiszewski S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 64: 689-695, 2004.
9. Bai L and Merchant JL. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J Biol Chem 275: 30725-30733, 2000.
10. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, and Berger SL. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8: 1243-1254, 2001.
11. Barrasa JI, Olmo N, Santiago-Gomez A, Lecona E, Anglard P, Turnay J, and Lizarbe MA. Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells. Biochim Biophys Acta 1823: 570-581, 2012.
12. Belkina AC and Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer 12: 465-477, 2012.
13. Bernhard D, Ausserlechner MJ, Tonko M, Loffler M, Hartmann BL, Csordas A, and Kofler R. Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. Faseb J 13: 1991-2001, 1999.
14. Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem 45: 2095-2116, 2010.
15. Bolden JE, Peart MJ, and Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
16. Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, and Johnstone RW. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis 4: e519, 2013.
17. Boutillier AL, Trinh E, and Loeffler JP. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem 84: 814-828, 2003.
18. Boyes J, Byfield P, Nakatani Y, and Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396: 594-598, 1998.
19. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C, and Turner BM. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19: 1751-1759, 2005.
20. Braun H, Koop R, Ertmer A, Nacht S, and Suske G. Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res 29: 4994-5000, 2001.
21. Brooks CL and Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2: 456-462, 2011.
22. Buchwald M, Kramer OH, and Heinzel T. HDACi - targets beyond chromatin. Cancer Lett 280: 160-167, 2009.
23. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, and Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99: 11700-11705, 2002.
24. Carlisi D, Vassallo B, Lauricella M, Emanuele S, D'Anneo A, Di Leonardo E, Di Fazio P, Vento R, and Tesoriere G. Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 32: 177-184, 2008.
25. Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP, and Young BD. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39: 1165-1175, 2003.
26. Chen L, Fischle W, Verdin E, and Greene WC. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657, 2001.
27. Chen WY and Townes TM. Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc Natl Acad Sci U S A 97: 377-382, 2000.
28. Chen Z, Clark S, Birkeland M, Sung CM, Lago A, Liu R, Kirkpatrick R, Johanson K, Winkler JD, and Hu E. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett 188: 127-140, 2002.
29. Chiba T, Yokosuka O, Arai M, Tada M, Fukai K, Imazeki F, Kato M, Seki N, and Saisho H. Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol 41: 436-445, 2004.
30. Chirakkal H, Leech SH, Brookes KE, Prais AL, Waby JS, and Corfe BM. Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding. Oncogene 25: 7192-7200, 2006.
31. Choi HS, Lee JH, Park JG, and Lee YI. Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. Biochem Biophys Res Commun 296: 1005-1012, 2002.
32. Chou CW and Chen CC. HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett 582: 4059-4065, 2008.
33. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, and Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840, 2009.
34. Cucciolla V, Borriello A, Criscuolo M, Sinisi AA, Bencivenga D, Tramontano A, Scudieri AC, Oliva A, Zappia V, and Della Ragione F. Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor. Carcinogenesis 29: 560-567, 2008.
35. Cuisset L, Tichonicky L, Jaffray P, and Delpech M. The effects of sodium butyrate on transcription are mediated through activation of a protein phosphatase. J Biol Chem 272: 24148-24153, 1997.
36. Dai Y, Rahmani M, Dent P, and Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25: 5429-5444, 2005.
37. Darlyuk-Saadon I, Weidenfeld-Baranboim K, Yokoyama KK, Hai T, and Aronheim A. The bZIP repressor proteins, c-Jun dimerization protein 2 and activating transcription factor 3, recruit multiple HDAC members to the ATF3 promoter. Biochim Biophys Acta 1819: 1142-1153, 2012.
38. Daroqui MC and Augenlicht LH. Transcriptional attenuation in colon carcinoma cells in response to butyrate. Cancer Prev Res (Phila) 3: 1292-1302, 2010.
39. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 133: 2485S-2493S, 2003.
40. Delcuve GP, Khan DH, and Davie JR. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin Epigenetics 4: 5, 2012.
41. Denis GV, McComb ME, Faller DV, Sinha A, Romesser PB, and Costello CE. Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res 5: 502-511, 2006.
42. Dion MF, Altschuler SJ, Wu LF, and Rando OJ. Genomic characterization reveals a simple histone H4 acetylation code. Proc Natl Acad Sci U S A 102: 5501-5506, 2005.
43. Drogaris P, Villeneuve V, Pomies C, Lee EH, Bourdeau V, Bonneil E, Ferbeyre G, Verreault A, and Thibault P. Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation. Sci Rep 2: 220, 2012.
44. Duan H, Heckman CA, and Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-1619, 2005.
45. Duvic M and Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16: 1111-1120, 2007.
46. Ellis DJ, Lawman ZK, and Bonham K. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem Biophys Res Commun 367: 656-662, 2008.
47. Endo T, Kano K, and Naito K. Nuclear histone deacetylases are not required for global histone deacetylation during meiotic maturation in porcine oocytes. Biol Reprod 78: 1073-1080, 2008.
48. This reference has been deleted.
49. Endo T, Naito K, Aoki F, Kume S, and Tojo H. Changes in histone modifications during in vitro maturation of porcine oocytes. Mol Reprod Dev 71: 123-128, 2005.
50. Filippakopoulos P and Knapp S. The bromodomain interaction module. FEBS Lett 586: 2692-2704, 2012.
51. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH, and Knapp S. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149: 214-231, 2012.
52. Floyd SR, Pacold ME, Huang Q, Clarke SM, Lam FC, Cannell IG, Bryson BD, Rameseder J, Lee MJ, Blake EJ, Fydrych A, Ho R, Greenberger BA, Chen GC, Maffa A, Del Rosario AM, Root DE, Carpenter AE, Hahn WC, Sabatini DM, Chen CC, White FM, Bradner JE, and Yaffe MB. The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature 498: 246-250, 2013.
53. Gan Y, Shen YH, Wang J, Wang X, Utama B, Wang J, and Wang XL. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. J Biol Chem 280: 16467-16475, 2005.
54. Gao J, Chen T, Liu J, Liu W, Hu G, Guo X, Yin B, Gong Y, Zhao J, Qiang B, Yuan J, and Peng X. Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-trichostatin A through Sp1 binding site. Glia 57: 989-999, 2009.
55. Garcia-Manero G, Tambaro FP, Bekele NB, Yang H, Ravandi F, Jabbour E, Borthakur G, Kadia TM, Konopleva MY, Faderl S, Cortes JE, Brandt M, Hu Y, McCue D, Newsome WM, Pierce SR, de Lima M, and Kantarjian HM. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 30: 2204-2210, 2012.
56. Gaucher J, Boussouar F, Montellier E, Curtet S, Buchou T, Bertrand S, Hery P, Jounier S, Depaux A, Vitte AL, Guardiola P, Pernet K, Debernardi A, Lopez F, Holota H, Imbert J, Wolgemuth DJ, Gerard M, Rousseaux S, and Khochbin S. Bromodomain-dependent stage-specific male genome programming by Brdt. EMBO J 31: 3809-3820, 2012.
57. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, and Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 310: 529-536, 2003.
58. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, and Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163, 2003.
59. Gronroos E, Hellman U, Heldin CH, and Ericsson J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 10: 483-493, 2002.
60. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
61. Gu W and Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595-606, 1997.
62. Gupta M, Han JJ, Stenson M, Wellik L, and Witzig TE. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26: 1356-1364, 2012.
63. Haigentz M, Jr., Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, and Haddad RI. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 48: 1281-1288, 2012.
64. Han S, Lu J, Zhang Y, Cheng C, Li L, Han L, and Huang B. HDAC inhibitors TSA and sodium butyrate enhanced the human IL-5 expression by altering histone acetylation status at its promoter region. Immunol Lett 108: 143-150, 2007.
65. Hargreaves DC, Horng T, and Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138: 129-145, 2009.
66. Heerdt BG, Houston MA, Anthony GM, and Augenlicht LH. Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity. Cancer Res 59: 1584-1591, 1999.
67. Heruth DP, Zirnstein GW, Bradley JF, and Rothberg PG. Sodium butyrate causes an increase in the block to transcriptional elongation in the c-myc gene in SW837 rectal carcinoma cells. J Biol Chem 268: 20466-20472, 1993.
68. Hezroni H, Sailaja BS, and Meshorer E. Pluripotency-related, valproic acid (VPA)-induced genome-wide histone H3 lysine 9 (H3K9) acetylation patterns in embryonic stem cells. J Biol Chem 286: 35977-35988, 2011.
69. Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, Furuichi K, and Sakai T. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 22: 7762-7773, 2003.
70. Hong L, Schroth GP, Matthews HR, Yau P, and Bradbury EM. Studies of the DNA-binding properties of histone H4 amino terminus - thermal-denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 tail to DNA. J Biol Chem 268: 305-314, 1993.
71. Huang W, Zhao S, Ammanamanchi S, Brattain M, Venkatasubbarao K, and Freeman JW. Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J Biol Chem 280: 10047-10054, 2005.
72. Hyland EM, Cosgrove MS, Molina H, Wang D, Pandey A, Cottee RJ, and Boeke JD. Insights into the role of histone H3 and histone H4 core modifiable residues in Saccharomyces cerevisiae. Mol Cell Biol 25: 10060-10070, 2005.
73. Ianari A, Gallo R, Palma M, Alesse E, and Gulino A. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J Biol Chem 279: 30830-30835, 2004.
74. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, and Ge H. Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 7: 689-692, 1997.
75. Johnson CA, White DA, Lavender JS, O'Neill LP, and Turner BM. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J Biol Chem 277: 9590-9597, 2002.
76. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002.
77. Johnstone RW and Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18, 2003.
78. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, Rudek MA, Belinsky SA, Herman JG, Baylin SB, Brock MV, and Rudin CM. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1: 598-607, 2011.
79. Kaneda R, Ueno S, Yamashita Y, Choi YL, Koinuma K, Takada S, Wada T, Shimada K, and Mano H. Genome-wide screening for target regions of histone deacetylases in cardiomyocytes. Circ Res 97: 210-218, 2005.
80. Kaufman JL, Fabre C, Lonial S, and Richardson PG. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clin Lymphoma Myeloma Leuk 13: 370-376, 2013.
81. Kelly WK and Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157, 2005.
82. Kiernan R, Bres V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, Jin DY, Emiliani S, and Benkirane M. Postactivation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278: 2758-2766, 2003.
83. Kim MY, Woo EM, Chong YT, Homenko DR, and Kraus WL. Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol 20: 1479-1493, 2006.
84. Kim TY, Kim IS, Jong HS, Lee JW, Kim TY, Jung M, and Bang YJ. Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells. Exp Mol Med 40: 639-646, 2008.
85. Kim YB, Lee KH, Sugita K, Yoshida M, and Horinouchi S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18: 2461-2470, 1999.
86. Kim YH, Park JW, Lee JY, and Kwon TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 25: 1813-1820, 2004.
87. Kim YJ, Greer CB, Cecchini KR, Harris LN, Tuck DP, and Kim TH. HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. Oncogene 32: 2828-2835, 2013.
88. Kostyniuk CL, Dehm SM, Batten D, and Bonham K. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene 21: 6340-6347, 2002.
89. Kramer OH, Baus D, Knauer SK, Stein S, Jager E, Stauber RH, Grez M, Pfitzner E, and Heinzel T. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 20: 473-485, 2006.
90. Krummel KA, Lee CJ, Toledo F, and Wahl GM. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci U S A 102: 10188-10193, 2005.
91. Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE, and Gschwend JE. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90: 535-541, 2004.
92. LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, and Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2: 67, 2009.
93. Lallemand F, Courilleau D, Sabbah M, Redeuilh G, and Mester J. Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. Biochem Biophys Res Commun 229: 163-169, 1996.
94. Lane AA and Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
95. Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, Flicke B, Ritscher A, Fedorowicz G, Vallero R, Ortwine DF, Gunzner J, Modrusan Z, Neumann L, Koth CM, Lupardus PJ, Kaminker JS, Heise CE, and Steiner P. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem 288: 26926-26943, 2013.
96. Lee AY, Paweletz CP, Pollock RM, Settlage RE, Cruz JC, Secrist JP, Miller TA, Stanton MG, Kral AM, Ozerova ND, Meng F, Yates NA, Richon V, and Hendrickson RC. Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry. J Proteome Res 7: 5177-5186, 2008.
97. Li L, He S, Sun JM, and Davie JR. Gene regulation by Sp1 and Sp3. Biochem Cell Biol 82: 460-471, 2004.
98. Liu Y, Denlinger CE, Rundall BK, Smith PW, and Jones DR. Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem 281: 31359-31368, 2006.
99. Lopez-Atalaya JP, Ito S, Valor LM, Benito E, and Barco A. Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition. Nucleic Acids Res 41: 8072-8074, 2013.
100. Lu Y and Lotan R. Transcriptional regulation by butyrate of mouse galectin-1 gene in embryonal carcinoma cells. Biochim Biophys Acta 1444: 85-91, 1999.
101. Luger K, Mader AW, Richmond RK, Sargent DF, and Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260, 1997.
102. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148, 2001.
103. Luo J, Su F, Chen D, Shiloh A, and Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408: 377-381, 2000.
104. Maier S, Daroqui MC, Scherer S, Roepcke S, Velcich A, Shenoy SM, Singer RH, and Augenlicht LH. Butyrate and vitamin D3 induce transcriptional attenuation at the cyclin D1 locus in colonic carcinoma cells. J Cell Physiol 218: 638-642, 2009.
105. Manohar M, Mooney AM, North JA, Nakkula RJ, Picking JW, Edon A, Fishel R, Poirier MG, and Ottesen JJ. Acetylation of histone H3 at the nucleosome dyad alters DNA-histone binding. J Biol Chem 284: 23312-23321, 2009.
106. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 3: 28-37, 2008.
107. Mariadason JM, Corner GA, and Augenlicht LH. Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60: 4561-4572, 2000.
108. Marks PA and Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107: 600-608, 2009.
109. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, and Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 19: 662-671, 2000.
110. Marzio G, Wagener C, Gutierrez MI, Cartwright P, Helin K, and Giacca M. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 275: 10887-10892, 2000.
111. Mersfelder EL and Parthun MR. The tale beyond the tail: histone core domain modifications and the regulation of chromatin structure. Nucleic Acids Res 34: 2653-2662, 2006.
112. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, and Anderson KC. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101: 4055-4062, 2003.
113. Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, and Shoemaker RH. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs 20: 682-692, 2009.
114. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
115. Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M, and Scarpa A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 1693: 167-176, 2004.
116. Munshi N, Merika M, Yie J, Senger K, Chen G, and Thanos D. Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell 2: 457-467, 1998.
117. Natoni F, Diolordi L, Santoni C, and Gilardini Montani MS. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta 1745: 318-329, 2005.
118. Noh EJ, Lim DS, Jeong G, and Lee JS. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindle checkpoint, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun 378: 326-331, 2009.
119. Nunes MJ, Milagre I, Schnekenburger M, Gama MJ, Diederich M, and Rodrigues E. Sp proteins play a critical role in histone deacetylase inhibitor-mediated derepression of CYP46A1 gene transcription. J Neurochem 113: 418-431, 2010.
120. Ozaki T, Okoshi R, Sang M, Kubo N, and Nakagawara A. Acetylation status of E2F-1 has an important role in the regulation of E2F-1-mediated transactivation of tumor suppressor p73. Biochem Biophys Res Commun 386: 207-211, 2009.
121. Papeleu P, Vanhaecke T, Elaut G, Vinken M, Henkens T, Snykers S, and Rogiers V. Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit Rev Toxicol 35: 363-378, 2005.
122. Patel JH, Du Y, Ard PG, Phillips C, Carella B, Chen CJ, Rakowski C, Chatterjee C, Lieberman PM, Lane WS, Blobel GA, and McMahon SB. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 24: 10826-10834, 2004.
123. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, Holloway AJ, and Johnstone RW. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 3697-3702, 2005.
124. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L, Porcellini A, Screpanti I, Balsano C, Alesse E, Gulino A, and Levrero M. Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 5: 552-558, 2003.
125. Pellizzaro C, Coradini D, Daniotti A, Abolafio G, and Daidone MG. Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. Int J Cancer 91: 654-657, 2001.
126. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, and Parsons PG. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 80: 1252-1258, 1999.
127. Ramirez-Carrozzi VR, Braas D, Bhatt DM, Cheng CS, Hong C, Doty KR, Black JC, Hoffmann A, Carey M, and Smale ST. A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling. Cell 138: 114-128, 2009.
128. Rando OJ. Combinatorial complexity in chromatin structure and function: revisiting the histone code. Curr Opin Genet Dev 22: 148-155, 2012.
129. Richon VM, Sandhoff TW, Rifkind RA, and Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97: 10014-10019, 2000.
130. Riggs MG, Whittaker RG, Neumann JR, and Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268: 462-465, 1977.
131. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, and Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 96: 4592-4597, 1999.
132. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, and Koeffler HP. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33: 53-61, 2005.
133. Sanchez R and Zhou MM. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Devel 12: 659-665, 2009.
134. Sapetschnig A, Rischitor G, Braun H, Doll A, Schergaut M, Melchior F, and Suske G. Transcription factor Sp3 is silenced through SUMO modification by PIAS1. EMBO J 21: 5206-5215, 2002.
135. Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M, Manda T, and Mutoh S. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69: 603-616, 2005.
136. Schnur N, Seuter S, Katryniok C, Radmark O, and Steinhilber D. The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes. Biochim Biophys Acta 1771: 1271-1282, 2007.
137. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, and Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27: 4784-4795, 2007.
138. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, and Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150, 1997.
139. Spiegel S, Milstien S, and Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31: 537-551, 2012.
140. St Germain C, O'Brien A, and Dimitroulakos J. Activating transcription factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination. Cancer Cell Int 10: 32, 2010.
141. Stimson L and La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 280: 177-183, 2009.
142. Strahl BD and Allis CD. The language of covalent histone modifications. Nature 403: 41-45, 2000.
143. Sun JM, Chen HY, Moniwa M, Litchfield DW, Seto E, and Davie JR. The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2. J Biol Chem 277: 35783-35786, 2002.
144. Suzuki T, Kimura A, Nagai R, and Horikoshi M. Regulation of interaction of the acetyltransferase region of p300 and the DNA-binding domain of Sp1 on and through DNA binding. Genes Cells 5: 29-41, 2000.
145. Swingler TE, Kevorkian L, Culley KL, Illman SA, Young DA, Parker AE, Lohi J, and Clark IM. MMP28 gene expression is regulated by Sp1 transcription factor acetylation. Biochem J 427: 391-400, 2010.
146. Tang Y, Luo J, Zhang W, and Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827-839, 2006.
147. Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami S, Matsunaga T, Takayama T, Kato J, and Niitsu Y. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 63: 8948-8954, 2003.
148. To KK, Polgar O, Huff LM, Morisaki K, and Bates SE. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res 6: 151-164, 2008.
149. Tomita A, Towatari M, Tsuzuki S, Hayakawa F, Kosugi H, Tamai K, Miyazaki T, Kinoshita T, and Saito H. c-Myb acetylation at the carboxyl-terminal conserved domain by transcriptional co-activator p300. Oncogene 19: 444-451, 2000.
150. Tropberger P, Pott S, Keller C, Kamieniarz-Gdula K, Caron M, Richter F, Li G, Mittler G, Liu ET, Buhler M, Margueron R, and Schneider R. Regulation of transcription through acetylation of H3K122 on the lateral surface of the histone octamer. Cell 152: 859-872, 2013.
151. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, and Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 673-678, 2005.
152. Vaziri C, Stice L, and Faller DV. Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ 9: 465-474, 1998.
153. Vervoorts J, Luscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, Austen M, and Luscher B. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep 4: 484-490, 2003.
154. Vidali G, Boffa LC, Bradbury EM, and Allfrey VG. Butyrate supression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase sensitivity of the associated DNA sequences. Proc Natl Acad Sci U S A 75: 2239-2243, 1978.
155. Vidali G, Gershey EL, and Allfrey VG. Chemical studies of histone acetylation. The distribution of epsilon-N-acetyllysine in calf thymus histones. J Biol Chem 243: 6361-6366, 1968.
156. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, and Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18: 7016-7025, 1999.
157. Waby JS, Bingle CD, and Corfe BM. Post-translational control of sp-family transcription factors. Curr Genomics 9: 301-311, 2008.
158. Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD, and Corfe BM. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 9: 275, 2010.
159. Walker GE, Wilson EM, Powell D, and Oh Y. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology 142: 3817-3827, 2001.
160. Wallace DM and Cotter TG. Histone deacetylase activity in conjunction with E2F-1 and p53 regulates Apaf-1 expression in 661W cells and the retina. J Neurosci Res 87: 887-905, 2009.
161. Waltzer L and Bienz M. Drosophila CBP represses the transcription factor TCF to antagonize wingless signalling. Nature 395: 521-525, 1998.
162. Wang H, Zhou W, Zheng Z, Zhang P, Tu B, He Q, and Zhu WG. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair (Amst) 11: 146-156, 2012.
163. Wang R, Cherukuri P, and Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J Biol Chem 280: 11528-11534, 2005.
164. Wang R, Li Q, Helfer CM, Jiao J, and You J. Bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J Biol Chem 287: 10738-10752, 2012.
165. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, and Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138: 1019-1031, 2009.
166. Watanabe K, Okamoto K, and Yonehara S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 12: 10-18, 2005.
167. White NR, Mulligan P, King PJ, and Sanderson IR. Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells. J Pediatr Gastroenterol Nutr 42: 134-141, 2006.
168. Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks KM, Ralli R, Scott CL, Frenzel A, Villunger A, and Johnstone RW. Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 71: 3603-3615, 2011.
169. Wierstra I. Sp1: emerging roles - beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 372: 1-13, 2008.
170. Wilson AJ, Byun DS, Nasser S, Murray LB, Ayyanar K, Arango D, Figueroa M, Melnick A, Kao GD, Augenlicht LH, and Mariadason JM. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 19: 4062-4075, 2008.
171. Wilson AJ, Chueh AC, Togel L, Corner GA, Ahmed N, Goel S, Byun DS, Nasser S, Houston MA, Jhawer M, Smartt HJM, Murray LB, Nicholas C, Heerdt BG, Arango D, Augenlicht LH, and Mariadason JM. Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 70: 609-620, 2010.
172. Wilson AJ, Velcich A, Arango D, Kurland AR, Shenoy SM, Pezo RC, Levsky JM, Singer RH, and Augenlicht LH. Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res 62: 6006-6010, 2002.
173. Xiao H, Hasegawa T, and Isobe K. p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275: 1371-1376, 2000.
174. Xu J, Zhou JY, Wei WZ, Philipsen S, and Wu GS. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 68: 6718-6726, 2008.
175. Yang F, Baumann C, Viveiros MM, and De La Fuente R. Histone hyperacetylation during meiosis interferes with large-scale chromatin remodeling, axial chromatid condensation and sister chromatid separation in the mammalian oocyte. Int J Dev Biol 56: 889-899, 2012.
176. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, and Trepel JB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 31: 2128-2135, 2013.
177. Yee SB, Kim MS, Baek SJ, Kim GC, Yoo KS, Yoo YH, and Park BS. Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion. Int J Oncol 25: 1431-1436, 2004.
178. Yokota T, Matsuzaki Y, Miyazawa K, Zindy F, Roussel MF, and Sakai T. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. Oncogene 23: 5340-5349, 2004.
179. Yuan ZL, Guan YJ, Chatterjee D, and Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307: 269-273, 2005.
180. Zeissig S, Fromm A, Mankertz J, Weiske J, Zeitz M, Fromm M, and Schulzke JD. Butyrate induces intestinal sodium absorption via Sp3-mediated transcriptional upregulation of epithelial sodium channels. Gastroenterology 132: 236-248, 2007.
181. Zelko IN and Folz RJ. Sp1 and Sp3 transcription factors mediate trichostatin A-induced and basal expression of extracellular superoxide dismutase. Free Radic Biol Med 37: 1256-1271, 2004.
182. Zentner GE and Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol 20: 259-266, 2013.
183. Zhang C, Richon V, Ni X, Talpur R, and Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125: 1045-1052, 2005.
184. Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ, Humphries AE, Nguyen DM, Trepel JB, Yu X, and Schrump DS. Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 7: 1388-1397, 2008.
185. Zhao R, Nakamura T, Fu Y, Lazar Z, and Spector DL. Gene bookmarking accelerates the kinetics of post-mitotic transcriptional re-activation. Nat Cell Biol 13: 1295-1304, 2011.
186. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, and Zhu WG. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26: 2782-2790, 2006.
187. Zhou Y, Schmitz KM, Mayer C, Yuan X, Akhtar A, and Grummt I. Reversible acetylation of the chromatin remodelling complex NoRC is required for non-coding RNA-dependent silencing. Nat Cell Biol 11: 1010-1016, 2009.
188. Zhu WG, Lakshmanan RR, Beal MD, and Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327-1333, 2001.
189. Zhuang S. Regulation of STAT signaling by acetylation. Cell Signal 25: 1924-1931, 2013.
190. Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J, Nair S, and Chen LF. Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. Oncogene [Epub ahead of print]; DOI: 10.1038/onc.2013.179, 2013.